263 related articles for article (PubMed ID: 17890213)
1. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer.
Monnier A
Ann Oncol; 2007 Sep; 18 Suppl 8():viii36-44. PubMed ID: 17890213
[TBL] [Abstract][Full Text] [Related]
2. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
4. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
6. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.
Jonat W; Hilpert F
J Cancer Res Clin Oncol; 2006 Jun; 132(6):343-55. PubMed ID: 16450161
[TBL] [Abstract][Full Text] [Related]
8. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
9. Reducing the risk of late recurrence in hormone-responsive breast cancer.
Cufer T
Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
[TBL] [Abstract][Full Text] [Related]
10. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
11. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS
Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
[TBL] [Abstract][Full Text] [Related]
12. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
13. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
Bauerschlag D; Schem C; Maass N; Jonat W
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Tobias JS
Ann Oncol; 2004 Dec; 15(12):1738-47. PubMed ID: 15550578
[TBL] [Abstract][Full Text] [Related]
15. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
16. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Esteva FJ; Hortobagyi GN
Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
[TBL] [Abstract][Full Text] [Related]
18. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Abdulhaq H; Geyer C
Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
[TBL] [Abstract][Full Text] [Related]
19. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
20. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
